December 12, 2024

Endolytix

Endolytix is using enzymes from bacteriophages to target antibiotic resistant nontuberculous mycobacteria (NTM) that cause chronic lung disease.

October 20, 2023

FastBack Bio

FastBack Bio is a biotechnology company with a novel CAR-T platform. FastBack Bio will develop CAR-T therapeutics with a novel co-stimulatory domain, M83, from its in-licensed platform.

September 26, 2023

InceptorBio

Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs.

September 26, 2023

EnteroBiotix

EnteroBiotix is a clinical-stage Microbiome biotech focused on developing therapeutics for Hepatic Encephalopathy and Graft vs. Host Disease.

September 26, 2023

AMYLYX

Amylyx is a pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders.